Tags

Type your tag names separated by a space and hit enter

Morin hydrate inhibits platelet activation and clot retraction by regulating integrin αIIbβ3, TXA2, and cAMP levels.
Eur J Pharmacol 2019; 865:172734EJ

Abstract

Morin hydrate is an active constituent of Morus alba L, Prunus dulcis, and Cudrania tricuspidata and has been reported to inhibit platelet activation in vivo and in vitro, but no reports have been issued on its regulation of αIIbβ3, a platelet-specific integrin and thromboxane A2 (TXA2), positive feedback molecule. In this study, we investigated the anti-platelet activity of morin hydrate in collagen- and thrombin-induced human platelets and attempted to identify the mechanism responsible for integrin αIIbβ3 activation and TXA2 generation. Our results demonstrated that morin hydrate (25-100 μM) inhibited collagen- and thrombin-induced platelet aggregation, granule secretion (P-selectin expression, ATP, and serotonin release), calcium mobilization, TXA2 production, integrin αIIbβ3 activation, and clot retraction. Additionally, morin hydrate attenuated the phosphorylations of phospholipase Cγ2 (PLCγ2), cytosolic phospholipase A2 (cPLA2), phosphoinositide 3-kinase (PI3K), Akt, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK), and enhanced the phosphorylations of inositol trisphosphate receptor (IP3 receptor) and cyclic adenosine monophosphate (cAMP) generation. However, it had no effect on the coagulation pathway. Taken together, these observations indicate morin hydrate inhibits platelet-mediated thrombosis by down-regulating TXA2 production and integrin αIIbβ3 activation, and by upregulating cAMP generation, and thus, inhibits clot retraction. These results suggest morin hydrate may have therapeutic potential as a treatment for platelet-activation-related diseases.

Authors+Show Affiliations

Department of Pharmacology and Intractable Disease Research Center, School of Medicine, Dongguk University, Gyeongju, Gyeongsangbuk-do, 38066, Republic of Korea.Department of Pharmacology and Intractable Disease Research Center, School of Medicine, Dongguk University, Gyeongju, Gyeongsangbuk-do, 38066, Republic of Korea.Department of Pharmacology and Intractable Disease Research Center, School of Medicine, Dongguk University, Gyeongju, Gyeongsangbuk-do, 38066, Republic of Korea. Electronic address: namks@dongguk.ac.kr.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31614139

Citation

Nam, Gi Suk, et al. "Morin Hydrate Inhibits Platelet Activation and Clot Retraction By Regulating Integrin αIIbβ3, TXA2, and cAMP Levels." European Journal of Pharmacology, vol. 865, 2019, p. 172734.
Nam GS, Lee KS, Nam KS. Morin hydrate inhibits platelet activation and clot retraction by regulating integrin αIIbβ3, TXA2, and cAMP levels. Eur J Pharmacol. 2019;865:172734.
Nam, G. S., Lee, K. S., & Nam, K. S. (2019). Morin hydrate inhibits platelet activation and clot retraction by regulating integrin αIIbβ3, TXA2, and cAMP levels. European Journal of Pharmacology, 865, p. 172734. doi:10.1016/j.ejphar.2019.172734.
Nam GS, Lee KS, Nam KS. Morin Hydrate Inhibits Platelet Activation and Clot Retraction By Regulating Integrin αIIbβ3, TXA2, and cAMP Levels. Eur J Pharmacol. 2019 Oct 12;865:172734. PubMed PMID: 31614139.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Morin hydrate inhibits platelet activation and clot retraction by regulating integrin αIIbβ3, TXA2, and cAMP levels. AU - Nam,Gi Suk, AU - Lee,Kyu-Shik, AU - Nam,Kyung-Soo, Y1 - 2019/10/12/ PY - 2019/07/31/received PY - 2019/10/10/revised PY - 2019/10/11/accepted PY - 2019/10/16/pubmed PY - 2019/10/16/medline PY - 2019/10/16/entrez KW - Cardiovascular disease KW - Clot retraction KW - Integrin α(IIb)β(3) KW - Morin hydrate KW - Platelet aggregation KW - Thrombosis SP - 172734 EP - 172734 JF - European journal of pharmacology JO - Eur. J. Pharmacol. VL - 865 N2 - Morin hydrate is an active constituent of Morus alba L, Prunus dulcis, and Cudrania tricuspidata and has been reported to inhibit platelet activation in vivo and in vitro, but no reports have been issued on its regulation of αIIbβ3, a platelet-specific integrin and thromboxane A2 (TXA2), positive feedback molecule. In this study, we investigated the anti-platelet activity of morin hydrate in collagen- and thrombin-induced human platelets and attempted to identify the mechanism responsible for integrin αIIbβ3 activation and TXA2 generation. Our results demonstrated that morin hydrate (25-100 μM) inhibited collagen- and thrombin-induced platelet aggregation, granule secretion (P-selectin expression, ATP, and serotonin release), calcium mobilization, TXA2 production, integrin αIIbβ3 activation, and clot retraction. Additionally, morin hydrate attenuated the phosphorylations of phospholipase Cγ2 (PLCγ2), cytosolic phospholipase A2 (cPLA2), phosphoinositide 3-kinase (PI3K), Akt, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK), and enhanced the phosphorylations of inositol trisphosphate receptor (IP3 receptor) and cyclic adenosine monophosphate (cAMP) generation. However, it had no effect on the coagulation pathway. Taken together, these observations indicate morin hydrate inhibits platelet-mediated thrombosis by down-regulating TXA2 production and integrin αIIbβ3 activation, and by upregulating cAMP generation, and thus, inhibits clot retraction. These results suggest morin hydrate may have therapeutic potential as a treatment for platelet-activation-related diseases. SN - 1879-0712 UR - https://www.unboundmedicine.com/medline/citation/31614139/Morin_hydrate_inhibits_platelet_activation_and_clot_retraction_by_regulating_integrin_αIIbβ3,_TXA2,_and_cAMP_levels L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(19)30686-7 DB - PRIME DP - Unbound Medicine ER -